Dette randomiserede forsøg med patienter med metastatisk colorectal- cancer, som tidligere havde fået behandling med oxaliplatin plus fluoropyrimidin for metastatisk sygdom, sammenlignede kombinationen af cetuximab og irinotecan (648 patienter) med irinotecan alene (650 patienter).
This randomised study in patients with metastatic colorectal cancer who had received initial combination treatment with oxaliplatin plus fluoropyrimidine for metastatic disease compared the combination of cetuximab and irinotecan (648 patients) with irinotecan alone (650 patients).